Astria Therapeutics (ATXS)
(Delayed Data from NSDQ)
$9.47 USD
+0.46 (5.11%)
Updated May 31, 2024 04:00 PM ET
After-Market: $9.48 +0.01 (0.11%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth F Momentum F VGM
Brokerage Reports
Astria Therapeutics, Inc. [ATXS]
Reports for Purchase
Showing records 61 - 69 ( 69 total )
Company: Astria Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Execution Is Always A Good Thing - Efforts On Track In 1Q22
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Astria Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1Q22 Results; STAR-0215 Close Clinical Development; IND Submission Mid-2022
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Astria Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2021 Results; Clinical Development Plans Make Us Starry-Eyed; STAR-0215 Phase 1a Study Coming Soon
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Astria Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Hoping To See A Sky Full Of Stars For ATXS and STAR-0215
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Astria Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Differentiation is Key; STAR-0215 Keeps Demonstrating Favorable Preclinical Properties
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Astria Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Time After Time - Looking Ahead to 2022 And STAR-0215 Data
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Astria Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
3Q21 Results; The Brewing Excitement for STAR-0215 is Palpable
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Astria Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Nice Boost to STAR-0215 Profile; Differentiation Appears Clear to Us
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J